[{"address1": "1359 Broadway", "address2": "Suite 1710", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "212 433 3791", "website": "https://zentalis.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 124, "companyOfficers": [{"maxAge": 1, "name": "Dr. Kimberly Lynn Blackwell M.D.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1173507, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cameron S. Gallagher M.B.A.", "age": 53, "title": "Co-Founder, President, Interim CFO, Interim Treasurer & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 892152, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  Paul J.D.", "age": 42, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 682466, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vincent  Vultaggio", "age": 40, "title": "VP of Finance & Interim Principal Accounting Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Lackner Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Chief Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kyle  Rasbach Ph.D., Pharm.D.", "age": 43, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.73, "open": 2.74, "dayLow": 2.71, "dayHigh": 3.34, "regularMarketPreviousClose": 2.73, "regularMarketOpen": 2.74, "regularMarketDayLow": 2.71, "regularMarketDayHigh": 3.34, "beta": 1.701, "forwardPE": -0.929972, "volume": 2814684, "regularMarketVolume": 2814684, "averageVolume": 1927093, "averageVolume10days": 1547420, "averageDailyVolume10Day": 1547420, "bid": 3.32, "ask": 3.35, "bidSize": 400, "askSize": 600, "marketCap": 236078560, "fiftyTwoWeekLow": 2.66, "fiftyTwoWeekHigh": 18.24, "priceToSalesTrailing12Months": 5.8204775, "fiftyDayAverage": 3.2978, "twoHundredDayAverage": 8.348025, "currency": "USD", "enterpriseValue": -146279552, "floatShares": 50960947, "sharesOutstanding": 71108000, "sharesShort": 7658786, "sharesShortPriorMonth": 11696892, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.107700005, "heldPercentInsiders": 0.03475, "heldPercentInstitutions": 1.05666, "shortRatio": 2.06, "shortPercentOfFloat": 0.2173, "bookValue": 5.38, "priceToBook": 0.61710036, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -194654000, "trailingEps": -2.64, "forwardEps": -3.57, "enterpriseToRevenue": -3.606, "enterpriseToEbitda": 0.667, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ZNTL", "underlyingSymbol": "ZNTL", "shortName": "Zentalis Pharmaceuticals, Inc.", "longName": "Zentalis Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1585920600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "39a4bee6-8ddb-3930-b936-d5bcf9eb8cf7", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.32, "targetHighPrice": 20.0, "targetLowPrice": 4.0, "targetMeanPrice": 9.9, "targetMedianPrice": 8.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 426384992, "totalCashPerShare": 5.996, "ebitda": -219216992, "totalDebt": 44027000, "quickRatio": 6.393, "currentRatio": 6.592, "totalRevenue": 40560000, "debtToEquity": 11.508, "revenuePerShare": 0.572, "returnOnAssets": -0.24767, "returnOnEquity": -0.42990002, "freeCashflow": -71432624, "operatingCashflow": -166376992, "grossMargins": 1.0, "operatingMargins": -5.4377003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-04"}]